Treatment strategies for combining immunostimulatory oncolytic virus therapeutics with dendritic cell injections

  • Received: 01 October 2014 Accepted: 29 June 2018 Published: 01 August 2015
  • MSC : Primary: 92C50, 92B05; Secondary: 37N25.

  • Oncolytic viruses (OVs) are used to treat cancer, as they selectively replicate inside of and lyse tumor cells. The efficacy of this process is limited and new OVs are being designed to mediate tumor cell release of cytokines and co-stimulatory molecules, which attract cytotoxic T cells to target tumor cells, thus increasing the tumor-killing effects of OVs. To further promote treatment efficacy, OVs can be combined with other treatments, such as was done by Huang et al., who showed that combining OV injections with dendritic cell (DC) injections was a more effective treatment than either treatment alone. To further investigate this combination, we built a mathematical model consisting of a system of ordinary differential equations and fit the model to the hierarchical data provided from Huang et al. We used the model to determine the effect of varying doses of OV and DC injections and to test alternative treatment strategies. We found that the DC dose given in Huang et al. was near a bifurcation point and that a slightly larger dose could cause complete eradication of the tumor. Further, the model results suggest that it is more effective to treat a tumor with immunostimulatory oncolytic viruses first and then follow-up with a sequence of DCs than to alternate OV and DC injections. This protocol, which was not considered in the experiments of Huang et al., allows the infection to initially thrive before the immune response is enhanced. Taken together, our work shows how the ordering, temporal spacing, and dosage of OV and DC can be chosen to maximize efficacy and to potentially eliminate tumors altogether.

    Citation: Joanna R. Wares, Joseph J. Crivelli, Chae-Ok Yun, Il-Kyu Choi, Jana L. Gevertz, Peter S. Kim. Treatment strategies for combining immunostimulatory oncolytic virus therapeutics with dendritic cell injections[J]. Mathematical Biosciences and Engineering, 2015, 12(6): 1237-1256. doi: 10.3934/mbe.2015.12.1237

    Related Papers:

  • Oncolytic viruses (OVs) are used to treat cancer, as they selectively replicate inside of and lyse tumor cells. The efficacy of this process is limited and new OVs are being designed to mediate tumor cell release of cytokines and co-stimulatory molecules, which attract cytotoxic T cells to target tumor cells, thus increasing the tumor-killing effects of OVs. To further promote treatment efficacy, OVs can be combined with other treatments, such as was done by Huang et al., who showed that combining OV injections with dendritic cell (DC) injections was a more effective treatment than either treatment alone. To further investigate this combination, we built a mathematical model consisting of a system of ordinary differential equations and fit the model to the hierarchical data provided from Huang et al. We used the model to determine the effect of varying doses of OV and DC injections and to test alternative treatment strategies. We found that the DC dose given in Huang et al. was near a bifurcation point and that a slightly larger dose could cause complete eradication of the tumor. Further, the model results suggest that it is more effective to treat a tumor with immunostimulatory oncolytic viruses first and then follow-up with a sequence of DCs than to alternate OV and DC injections. This protocol, which was not considered in the experiments of Huang et al., allows the infection to initially thrive before the immune response is enhanced. Taken together, our work shows how the ordering, temporal spacing, and dosage of OV and DC can be chosen to maximize efficacy and to potentially eliminate tumors altogether.


    加载中
    [1] Surgery, 156 (2014), 263-269.
    [2] J. Theor. Biol., 225 (2003), 257-274.
    [3] PLoS Comput. Biol., 7 (2011), e1001085.
    [4] J. Theor. Biol., 252 (2008), 109-122.
    [5] Bull. Math. Biol., 72 (2010), 469-489.
    [6] Immunity, 21 (2004), 341-347.
    [7] Cancer Res., 61 (2001), 5453-5460.
    [8] J. Virol., 75 (2001), 10663-10669.
    [9] Front Oncol, 3 (2013), p56.
    [10] Cancer Res., 67 (2007), p8420.
    [11] Clin. Cancer Res., 13 (2007), 4677-4685.
    [12] Cancer Gene Ther., 16 (2009), 873-882.
    [13] Cancer Gene Ther., 18 (2011), 305-317.
    [14] Bull. Math. Biol., 73 (2011), 2-32.
    [15] Expert Rev Vaccines, 12 (2013), 1155-1172.
    [16] Cancer Res., 66 (2006), 2314-2319.
    [17] J. Virol., 74 (2000), 2895-2899.
    [18] Mol. Ther., 18 (2010), 264-274.
    [19] J. Virol., 80 (2006), 3549-3558.
    [20] Biomaterials, 31 (2010), 1865-1874.
    [21] Biomaterials, 32 (2011), 2314-2326.
    [22] (submitted).
    [23] Nat. Med., 7 (2001), 781-787.
    [24] J. Theor. Biol., 263 (2010), 530-543.
    [25] PLoS ONE, 5 (2010), e15482.
    [26] Nat Commun, 4 (2013), p1974.
    [27] Mol. Ther., 18 (2010), 888-895.
    [28] Gene Ther., 15 (2008), 247-256.
    [29] J. Theor. Biol., 239 (2006), 334-350.
    [30] Mol. Ther., 19 (2011), 1008-1016.
    [31] Nat. Rev. Microbiol., 12 (2014), 23-34.
    [32] Clin. Cancer Res., 15 (2009), 2352-2360.
    [33] Bioinformatics, 30 (2014), 1884-1891.
    [34] J. Theor. Biol., 294 (2012), 56-73.
    [35] Gene Ther., 19 (2012), 543-549.
    [36] Nat. Biotechnol., 30 (2012), 658-670.
    [37] Clin. Cancer Res., 18 (2012), 6679-6689.
    [38] Nat Immunol., 2 (2001), 423-429.
    [39] Nat Immunol., 1 (2000), 47-53.
    [40] Mol. Cancer Ther., 5 (2006), 362-366.
    [41] Cancer Res., 61 (2001), 3501-3507.
    [42] Math Biosci Eng, 10 (2013), 939-957.
    [43] PLoS ONE, 4 (2009), e4271.
    [44] Hum. Gene Ther., 8 (1997), 37-44.
    [45] Bull. Math. Biol., 66 (2004), 605-625.
    [46] Pathol. Oncol. Res., 18 (2012), 771-781.
    [47] Neoplasia, 15 (2013), 591-599.
  • Reader Comments
  • © 2015 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(1661) PDF downloads(661) Cited by(24)

Article outline

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog